GC Biopharma operating profit up 40% despite lower sales; target price KRW 190,000 maintained
Predicted impact: Low
Same Q3 profit up 40% and KRW 190,000 target already covered in recent items.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.